Peripheral areas of nonperfusion in treated central retinal vein occlusion as imaged by wide-field fluorescein angiography

Retina

Volumn 31, Issue 5, 2011, Pages 829-837

  Spaide, Richard F ^a,b  

^a VITREOUS RETINA MACULA CONSULTANTS OF NEW YORK   (United States)

^b EAR AND THROAT HOSPITAL   (United States)

Author keywords

Central retinal vein occlusion; vascular endothelial growth factor; vascular nonperfusion

Indexed keywords

RANIBIZUMAB;

ADULT; AGED; ARTICLE; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; EYE; HUMAN; PERFUSION; PROSPECTIVE STUDY; RETINA; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA VEIN; SCANNING LASER OPHTHALMOSCOPE; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CROSS-SECTIONAL STUDIES; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; MIDDLE AGED; PROSPECTIVE STUDIES; RETINAL VEIN; RETINAL VEIN OCCLUSION; RETREATMENT; VISUAL ACUITY;

EID: 79955568224     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31820c841e     Document Type: Article

References (24)

1. Anderson DC, Lucas RA, Henderson R. Wide field scanning laser ophthalmoscope. US patent 5815242, September 29, 1998.
2. Boyd SR, Zachary I, Chakravarthy U, et al. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol 2002;120:1644-1645.
3. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:270-271.
4. Iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 2006;26: 279-284. (Pubitemid 44318180)
5. Ferrara DC, Koizumi H, Spaide RF. Early bevacizumab treatment of central retinal vein occlusion. Am J Ophthalmol 2007;144:864-871. (Pubitemid 350122344)
6. Costa RA, Jorge R, Calucci D, et al. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina. 2007;27:141-149.
7. Campochiaro PA, Hafiz G, Shah SM, et al. Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther 2008;16:791-799. (Pubitemid 351426182)
8. Pieramici DJ, Rabena M, Castellarin AA, et al. Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions. Ophthalmology. 2008;115: e47-e54.
9. Spaide RF, Chang LK, Klancnik JM, et al. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol 2009;147:298-306.
10. Rouvas A, Petrou P, Vergados I, et al. Intravitreal ranibizumab (Lucentis) for treatment of central retinal vein occlusion: a prospective study. Graefes Arch Clin Exp Ophthalmol 2009; 247:1609-1616.
11. method=detail&id=12367. Accessed December 24, 2009.
12. Duke-Elder S and Wybar KC. The anatomy of the visual system. In: Duke-Elder, ed. System of Ophthalmology. Vol II. St. Louis, MO: Mosby; 1961:220-271.
13. Straatsma BR, Landers MB, Kreiger AE, Apt L. Topography of the adult human retina. UCLA Forum Med Sci 1969;8: 379-410.
14. Drasdo N, Fowler CW. Non-linear projection of the retinal image in a wide-angle schematic eye. Br J Ophthalmol 1974; 58:709-714.
15. Taylor E, Jennings A. Calculation of total retinal area. Br J Ophthalmol 1971;55:262-265.
16. The Central Vein Occlusion Study Group N report. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. Ophthalmology 1995;102: 1434-1444.
17. Tolentino MJ, Miller JW, Gragoudas ES, et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 1996;103:1820-1828. (Pubitemid 26403735)
18. Tolentino MJ, McLeod DS, Taomoto M, et al. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol 2002;133:373-385. (Pubitemid 34171588)
19. Ferrara N. Binding to the extracellular matrix and proteolytic processing: two key mechanisms regulating vascular endothelial growth factor action. Mol Biol Cell 2010;21:687-690.
20. Hinow P, Gerlee P, McCawley LJ, et al. A spatial model of tumor-host interaction: application of chemotherapy. Math Biosci Eng 2009;6:521-546.
21. Beaumont PE, Kang HK. Pattern of vascular nonperfusion in retinal venous occlusions occurring within the optic nerve with and without optic nerve head swelling. Arch Ophthalmol 2000; 118:1357-1363.
22. Wroblewski JJ, Wells JA 3rd, Adamis AP, et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Arch Ophthalmol 2009;127:374-380.
23. Goldenberg-Cohen N, Dadon S, Avraham BC, et al. Molecular and histological changes following central retinal artery occlusion in a mouse model. Exp Eye Res 2008;87:327-333.
24. Hayreh SS, Weingeist TA. Experimental occlusion of the central retinal artery. IV. Retinal tolerance time to acute ischemia. Br J Ophthalmol 1980;818-825. (Pubitemid 11217119)